The 36-month beta value for INSM is at 1.29. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INSM is 174.62M, and currently, shorts hold a 8.64% of that float. The average trading volume for INSM on February 05, 2025 was 1.80M shares.
INSM) stock’s latest price update
Insmed Inc (NASDAQ: INSM)’s stock price has surge by 4.02relation to previous closing price of 77.88. Nevertheless, the company has seen a 3.25% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-10 that –ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million– –2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024– –NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S. Launch to the Third Quarter of 2025, Pending Approval Under Priority Review– –Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025– –Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026– –IND Cleared for Insmed’s First Gene Therapy (INS1201) for Patients with DMD; First Patient Dosing Anticipated in the First Half of 2025– BRIDGEWATER, N.J., Jan. 10, 2025 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company’s commercial and clinical programs and its outlook for 2025.
INSM’s Market Performance
Insmed Inc (INSM) has seen a 3.25% rise in stock performance for the week, with a 15.81% gain in the past month and a 20.41% surge in the past quarter. The volatility ratio for the week is 4.67%, and the volatility levels for the past 30 days are at 4.38% for INSM. The simple moving average for the past 20 days is 9.94% for INSM’s stock, with a 24.30% simple moving average for the past 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Truist repeating the rating for INSM by listing it as a “Buy.” The predicted price for INSM in the upcoming period, according to Truist is $48 based on the research report published on April 23, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see INSM reach a price target of $42. The rating they have provided for INSM stocks is “Outperform” according to the report published on February 15th, 2024.
Wells Fargo gave a rating of “Overweight” to INSM, setting the target price at $55 in the report published on December 08th of the previous year.
INSM Trading at 11.14% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.47% of gains for the given period.
Volatility was left at 4.38%, however, over the last 30 days, the volatility rate increased by 4.67%, as shares surge +15.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.89% upper at present.
During the last 5 trading sessions, INSM rose by +3.25%, which changed the moving average for the period of 200-days by +209.43% in comparison to the 20-day moving average, which settled at $73.69. In addition, Insmed Inc saw 17.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Lewis William, who proposed sale 25,580 shares at the price of $77.91 back on Feb 03 ’25. After this action, Lewis William now owns shares of Insmed Inc, valued at $1,992,928 using the latest closing price.
Schaeffer Orlov S Nicole, the Chief People Strategy Officer of Insmed Inc, sale 91,140 shares at $80.00 during a trade that took place back on Jan 30 ’25, which means that Schaeffer Orlov S Nicole is holding 97,083 shares at $7,291,200 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.14 for the present operating margin
- 0.77 for the gross margin
The net margin for Insmed Inc stands at -2.52. The total capital return value is set at -0.41. Equity return is now at value -890.75, with -51.17 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.62. The debt to equity ratio resting at 2.07. The interest coverage ratio of the stock is -9.15.
Currently, EBITDA for the company is -660.18 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 43.83. The receivables turnover for the company is 8.1for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.37.
Conclusion
In conclusion, Insmed Inc (INSM) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
